Clinical and preclinical data on monalizumab to be presented at AACR annual meeting 2017
Number of shares and voting rights of Innate Pharma as at february 7, 2017
Innate Pharma announces top-line results from EffiKIR trial evaluating the efficacy of lirilumab as a single agent in elderly patients with acute myeloid leukemia
2014 Half-year report on Innate Pharma’s liquidity contract with Gilbert Dupont
Innate Pharma receives $15 million milestone payment from Bristol-Myers Squibb for continued exploration of lirilumab in combination with Opdivo
Number of shares and voting rights of Innate Pharma as at January 5, 2017
Upcoming investor conferences
Innate Pharma announces its financial calendar for 2017
Innate Pharma announces key leadership and corporate governance changes to support next stage of development
Further clinical data for lirilumab and IPH4102 presented at ASH annual meeting reinforcing confidence in our programs
